OriCell Therapeutics
Business Services · China · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Building #1 1227 Zhangheng Rd Fl 3, Shan...Phone Number
+86 2168868119Website
www.oricell.comRevenue
$25.4 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About OriCell Therapeutics
Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. OriCell received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Venture Partners at the end of 2019 and completed the A round of financing worth over 200 million Yuan at the end of 2020.Explore more
OriCell Therapeutics Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is OriCell Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Check if OriCell Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on OriCell Therapeutics recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at OriCell Therapeutics
OriCell Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if OriCell Therapeutics had a recent Job posting/layoffs
Check out if OriCell Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once OriCell Therapeutics has new funding data
Product Launch: Get notified when OriCell Therapeutics launches new products
Recommended Actions
Reach out to Masked Content who joined OriCell Therapeutics as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
OriCell Therapeutics is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
OriCell Therapeutics is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about OriCell Therapeutics.
OriCell Therapeutics financials insights
Gather financial insights about OriCell Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Series B
$165M
2026
Series C
$70M
Other Financing Round
$110M
OriCell Therapeutics Tech Stack
A closer look at the technologies used by OriCell Therapeutics
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Funding
Funding
Funding
Funding
Open Position
Open Position
OriCell Therapeutics News & Media
ASCO 2026 | Oricell's GPC3 CAR-T Ori-C101 Hits 66.7% ORR in Late-Line HCC, Signaling Best-in-Class Potential
CHICAGO, May 31, 2026 /PRNewswire/ -- Oricell Therapeutics, a clinical-stage biotech company pioneering cancer immunotherapy, today announced that its lead asset, Ori-C101, a GPC3-targeted CAR-T therapy, achieved a 66.7% objective response rate (ORR) in patients with Late-line refractory...Oricell Therapeutics Closes $110 Million Pre-IPO Financing to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI, April 10, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell"), a global clinical-stage biotechnology company pioneering innovative cancer immunotherapies, today announced the cumulative closing of a pre-IPO financing round in excess of $110 million. The round was co-led by Vivo Capital, Beijing Medical and Health Care Industry Investment Fund, Qiming Venture Partners, and a leading global healthcare fund. The syndicate included an international sovereign wealth fund,Oricell Therapeutics Announces US$70M Initial Closing of Series C Financing, to Accelerate Global Development of Solid Tumor CAR-T Therapies
SHANGHAI and SAN FRANCISCO, Jan. 12, 2026 /PRNewswire/ -- Oricell Therapeutics Holdings Limited ("Oricell" or "the Company"), a global leader in innovative cancer immunotherapy, announced today the closing of a $70M Series C1 financing. The round was co-led by Beijing Medical and Health...Oricell Announces FDA Clearance of IND Application for OriCAR-017, a novel GPRC5D Targeted CAR-T Cell Therapy Utilizing the Company's Proprietary Platform, for the Treatment of Relapsed/Refractory Multiple Myeloma.
SHANGHAI and ROSELAND, N.J., Jan. 29, 2024 /PRNewswire/ -- Oricell Therapeutics (Oricell), a clinical-stage biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for OriCAR-017 for...
Read more news
Top Business Services Companies
Frequently Asked Questions Regarding OriCell Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2015, OriCell Therapeutics aims to develop drugs with good efficacy and affordable prices to satisfy the globally unmet clinical needs through innovations and strives to become the world-leading developer of novel drugs for tumor immunotherapy. OriCell received a pre-A round exclusive investment of nearly 100 million yuan from Qiming Ven... Read More
